Diagnostic Products

Cancer diagnostics & monitoring

Next-generation sequencing (NGS) continues to evolve. We are developing in vitro diagnostics (IVDs) and Personalized Cancer Monitoring (PCM™) for solid tumor biomarker identification.

Our products include

In Vitro Diagnostics

Solid tumor IVDs: FusionPlex® Dx and LiquidPlex Dx

(CE-marked for use in European Union jurisdictions) 

Invitae’s Anchored Multiplex PCR (AMP™) chemistry is now available as a CE-marked in-vitro diagnostic (IVD) test designed to identify actionable genomic alterations in tissue and blood samples. This test, intended for use as a companion diagnostic, enables broader patient access to the right cancer therapies at the right time.

Personalized Cancer Monitoring (PCM™)

Get ahead of cancer.

Invitae PCM is a pan-cancer*, tumor-informed liquid biopsy test that uses next-generation sequencing to detect minimal or molecular residual disease (MRD) in solid tumors.

*With exceptions—such as CNS malignancies and sarcomas—this test is not intended to be used in hematological malignancies such as leukemias or lymphomas. 

menu home-icon-silhouette remove-button twitter linkedin-1 facebook-circular-logo right